Jada Bascom Foundation
All conditions

Histiocytic disorders

Blastic plasmacytoid dendritic cell neoplasm

Also called: BPDCN · CD4+ CD56+ hematodermic neoplasm (historical) · Blastic NK-cell lymphoma · agranular CD4-positive natural killer cell leukaemia (historical)

What a donor has to do with this

For some people with this condition, a transplant using blood stem cells from an unrelated donor is part of the treatment guidelines. When a transplant is the right route and no one in the family matches, that donor comes from a registry. Not everyone with this condition has a transplant, and many never need one.

This is our reading of published transplant guidelines for this condition, not a measurement of how many people need a donor. Where a source actually counted donors, the figure and the people it counted are shown further down. Where none did, we say so rather than estimate.

What the evidence says

Who it affects
Typically diagnosed in older adults and is markedly more common in men, although it can occur at any age. Source population/region/year: international CIBMTR and peer-reviewed evidence, article published 2023.
Treatments other than a transplant
Tagraxofusp, a CD123-directed cytotoxin approved in the US in 2018, leukemia-based induction, other CD123-directed approaches and clinical trials; responders commonly proceed to allo-HCT rather than use these as proven curative substitutes
If a transplant is used, the cells come from
Allogeneic peripheral blood, bone marrow or cord blood from matched related, matched unrelated, haploidentical or other alternative donors; dominant source not reported in the opened disease-specific sources
How often the donor was unrelated
Not reported. No source we could read states this for this condition, so we do not give a number. An estimate here would be a guess dressed as evidence.

Where this gets complicated

WHO5 places BPDCN among histiocytic/dendritic neoplasms rather than conventional leukaemia. The transplant cohort is adult and transplant-selected; paediatric evidence and the optimal sequencing of tagraxofusp remain less certain.

Written for transplant clinicians, not for patients. We quote it so you can see what the guidance actually says:
“Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm”

It describes what teams consider in general. It cannot say what applies to any one person. Read the source.

People with this condition need donors

Joining a registry is a cheek swab and a short health form. You are contacted only if you turn out to be a possible match for someone, and you can ask questions and decline before anything else happens.

Find your registry

Related conditions

Others in histiocytic disorders. They are genuinely different diseases with different treatments — the group name is not a diagnosis.

Where this came from